---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003234"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T21:24:40.605424+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech acquires exclusive U.S. rights to OsStic fracture product; invests up to €8M for 12.5% of BMI

## Summary
- Exclusive U.S. license/distribution for OsStic and ARC delivery tech; initial five-year term with renewal options.
- Sanara invests up to €8M (€4M initial incl. debt conversion) for ~12.5% equity in BMI; remaining €4M tied to milestones.
- OsStic received FDA Breakthrough Device Designation Dec 2023; U.S. market launch expected Q1 2027.
- Targets >100,000 annual periarticular fracture procedures; complements existing surgical portfolio.
- Company's Chief Corporate Development Officer Tyler Palmer appointed to BMI board.

## SEC filing metadata
- accession: 0001493152-25-003234
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315225003234/0001493152-25-003234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315225003234/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003234
- JSON: https://secwatch.observer/filing/0001493152-25-003234.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003234.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.